Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models


Abstract

Purpose: Radium-223 dichloride (radium-223, Xofogo), a targeted alpha therapy, is currently used for the treatment of patients with castration-resistant prostate cancer (CRPC) with bone metastases. This study examines the mode-of-action and antitumor efficacy of radium-223 in two prostate cancer xenograft models. Experimental Design: Mice bearing intratibial LNCaP or LuCaP 58 tumors were randomized into groups (n = 12–17) based on lesion grade and/or serum PSA level and administered radium-223 (300 kBq/kg) or vehicle, twice at 4-week intervals. X-rays and serum samples were obtained biweekly. Soft tissue tumors were observed macroscopically at sacrifice. Tibiae were analyzed by gamma counter, micro-CT, autoradiography and histology.

Results: Radium-223 inhibited tumor-induced osteoblastic bone growth and protected normal bone architecture, leading to reduced bone volume in LNCaP and abiraterone-resistant LuCaP 58 models. Furthermore, radium-223 resulted in lower PSA values and reduced total tissue and tumor areas, indicating that treatment constrains prostate cancer growth in bone. In addition, radium-223 suppressed abnormal bone metabolic activity as evidenced by decreased number of osteoblasts and osteoclasts and reduced level of the bone formation marker PINP. Mode-of-action studies revealed that radium-223 was deposited in the intratumoral bone matrix. DNA double-strand breaks were induced in cancer cells within 24 hours after radium-223 treatment, and PSA levels were significantly lower 72 hours after treatment, providing further evidence of the antitumor effects.

Conclusions: Taken together, radium-223 therapy exhibits a dual targeting mode-of-action that induces tumor cell death and suppresses tumor-induced pathologic bone formation in tumor microenvironment of osseous CRPC growth in mice.

Introduction

Prostate cancer is the second most frequently diagnosed cancer worldwide and the third leading cause of cancer-related mortality in men in developed countries (1). Although surgery and radiotherapy offer effective treatment against localized prostate cancer, curative options for metastatic prostate cancer remain elusive. Hormone ablative therapy represents the most common therapeutic option for locally advanced or widespread prostate cancer. However, most patients eventually develop resistance to androgen deprivation therapy and progress towards the terminal stage of the disease, castration-resistant prostate cancer (CRPC). In addition to the treatment resistance, the risk of developing metastatic bone disease secondary to prostate cancer, and increased bone loss due to androgen deprivation therapy represent significant clinical obstacles in the treatment of patients with advanced prostate cancer (2).

Bone metastases accompanying prostate cancer feature a state of accelerated bone turnover with abnormal activation of both osteoclasts and osteoblasts, and consequent abnormal bone formation, resulting in fragile, disorganized woven bone (2). This leads to increased risk of skeletal fractures, immobility, severe bone pain, significant decrease in quality of life, increased mortality and, consequently, remarkable economic burden (3, 4). Therefore, the elimination of cancer in bone and the restoration and/or preservation of healthy bone morphology are important goals in the management and treatment of prostate cancer.

Abiraterone [cytochrome P (CYP17) inhibitor] and enzalutamide [androgen receptor inhibitor] have been approved by the FDA and the European Medicines Agency (EMA) for the treatment of patients with CRPC. Although these secondary androgen suppression agents show high efficacy in Phase III trials (5–8), their impact on bone microenvironment remains largely unknown. One report has suggested that CYP17 inhibition with abiraterone has direct effects on bone anabolic and antiresorptive activity (9).
Radium-223 dichloride (Xofigo) is the first targeted alpha therapy approved by FDA and EMA for the treatment of patients with CRPC with symptomatic bone metastases and no known visceral metastatic disease. Radium-223 is an alpha particle (α)-emitting calcium-mimetic that selectively binds to hydroxyapatite in the bone, targets areas of increased bone turnover such as osteoblastic bone metastases and improves the median overall survival in a large phase III trial in patients with CRPC and bone metastases (10). In addition, radium-223 has also been shown to significantly delay the manifestation of the first clinically identified symptomatic skeletal events (SSE; ref. 11).

In a mouse model of osteolytic breast cancer bone metastasis, radium-223 reduced development of osteolytic lesions and improved survival by inducing DNA double-strand breaks in tumor cells and decreasing the number of osteoclasts (12). Whether radium-223 impact on CRPC bone metastasis occurs via a similar mechanism has not been investigated yet. Here, we exploited two mouse models of osteoblastic reaction resulting from prostate cancer growth in the bone environment mimicking the devastating bone disease observed in prostate cancer patients to investigate the efficacy and mechanism-of-action of radium-223.

**Materials and Methods**

**Compounds**

Radium-223 was synthesized at Institute for Energy and Technology (Norway) as a solution containing 60 kBq/mL of radium-223 dichloride. Abiraterone acetate (abiraterone, Zytiga) was obtained from Janssen Biotech.

**Cells**

LNCaP cells were purchased from the ATCC (November 2013) and maintained in standard cell culture conditions as indicated by the provider for three weeks until the experiment was started. Cells were authenticated in June 2014 using short tandem repeat analysis (GenePrint10 system, Promega) at the Institute for Molecular Medicine Finland (FIMM, Helsinki, Finland). LuCaP 58 patient-derived xenograft (PDX) was licensed from the University of Washington (13) and propagated subcutaneously in intact male SCID mice (CB17/scr/crl, Charles River Laboratories) until the experiment was started (July 2013). LuCaP 58 tumors were demonstrated as Myeloplasma free in January 2013 using the IDEXX PCR test (IDEXX). For intratibial inoculation, tumors were harvested and processed to single-cell suspension as described below (13). Briefly, the cells were mechanically dissociated and placed in Hank’s balanced salt solution (HBSS). Red blood cells were lysed with a solution containing 0.15 mol/L NH₄Cl, 0.01 mol/L NaHCO₃, and 0.09 mmol/L EDTA using 5:1 (vol:vol) ratio at room temperature, and the reaction was stopped with 3-fold volume of HBSS. The cell suspension was washed at least two times with PBS. The viability of the cell suspension was approximately 90%.

**In vivo models**

All experiments were approved by the Animal Experiment Board of Finland and performed according to the guidelines of the European Union directive 2010/63/EU. Mice were kept under pathogen-free and controlled conditions and fed 2916 Teklad Global diet (Harlan Laboratories, B.V., Horst, the Netherlands). The effects of radium-223 were studied in cell line-based LNCaP and patient-derived LuCaP 58 prostate xenograft models in mice. With LuCaP 58 mice, three individual studies were carried out to assess the efficacy and mechanism-of-action of radium-223 as well as sensitivity for abiraterone. The administration dose of 300 kBq/kg was selected based on a previous dose escalation study in mouse model of breast cancer bone metastasis, representing 12% of the severely toxic dose of radium-223 to 10% of the mice (STD10) after single administration (12). For the cell line-based model, LNCaP cells (2 × 10⁶ cells in 20 µL of PBS) were inoculated into the right proximal tibia of 7-week-old male NOD SCID mice (NOD, CB17-Prkd⁻/⁻/NcrCrl, Charles River, Germany). The mice were anesthetized via isoflurane inhalation (IsoFlo vet, Abbot Laboratories). Analgesia was provided with buprenorphine (0.3 mg/mL Temgesic, RB Pharmaceuticals Ltd.) once before the intratibial inoculation (0.1 mg/kg, s.c.), and for 2 days after the intratibial inoculation and for the last 5 days of the experiment (0.02 mg/mL in drinking water). After 6 weeks, mice with tumor-induced osteoblastic, mixed and osteolytic changes as observed by radiography were randomized into two groups (n = 13–14 per group) based on lesion score (1–3) and serum prostate-specific antigen (PSA) value before treatment. Radium-223 (300 kBq/kg) and vehicle (28 mmol/L sodium citrate, Institute for Energy Technology, Norway) were administered intravenously (i.v.) one day after randomization, and at 4 weeks after first dose, followed by sacrifice 6 weeks after the first dose.

Blood samples were collected from the saphenous vein 6 weeks after LNCaP tumor cell inoculation and biweekly thereafter and additionally by cardiac puncture at sacrifice. Body weight was measured twice weekly. Tumors in soft tissues, including liver, adrenal glands, heart, lungs and pancreas, were observed macroscopically at sacrifice. The tumor-bearing and contralateral healthy tibiae were collected, weighed and measured for radium-223 activity using a gamma counter (1260 Multigamma II, LKB/Wallac). Serum PSA levels were analyzed using the...
Quantikine Human Kallikrein 3/PSA Enzyme-Linked Immunoassay Kit (R&D Systems) and N-terminal propeptide of type 1 procollagen (PINP) concentration was determined using the Rat/Mouse PINP enzymeimmunoassay (EIA) Kit (IDS Ltd.).

For the PDX model, LuCaP 58 cells as single-cell suspension of 1 × 10^6 cells in 20 μL of PBS harvested from subcutaneous tumors were inoculated into the bone marrow cavity of SCID mice (Charles River Laboratories). Mice with apparent bone changes at 7 or 9 weeks after tumor inoculation were selected for the study. Blood samples were collected at 3 weeks after cell inoculation, and biweekly thereafter as described above. To assess the efficacy, animals were randomized into two groups (n = 15–17/group) based on serum PSA levels; the first mice reached the inclusion criteria (PSA > 1 ng/mL) at 7 weeks and the rest at 9 weeks after tumor inoculation. Radium-223 (300 kBq/kg) or 28 mmol/L sodium citrate (vehicle) were administered intravenously on the first day after randomization and 4 weeks later, followed by sacrifice 6 weeks after the first dose, or earlier if weight loss exceeded 20%.

In the mode-of-action study, LuCaP 58 mice were randomized into groups (n = 12 per group) based on PSA level at 7 weeks after tumor inoculation. Radium-223 (300 kBq/kg) was administered as a single dose, followed by sacrifice at 24, 48, or 72 hours. Mice in the vehicle group were sacrificed at 72 hours.

For comparison of the efficacy between radium-223 and abiraterone in LuCaP 58 PDX model, mice were randomized (n = 17/group) based on serum PSA levels and administered with vehicle (28 mmol/L sodium citrate for radium-223 and 5% benzyl benzoate in 95% peanut oil for abiraterone). radium-223 (300 kBq/kg, i.v., on the first day after randomization and 4 weeks later) or abiraterone (daily, 200 mg/kg, p.o.), followed by sacrifice 6 weeks after the first dose.

Histology, histomorphometry, and autoradiography
Tibiae were fixed in 4% PFA (paraformaldehyde) for 1–2 days, decalcified in 14% to 10% EDTA for 2 weeks, processed to paraffin blocks and then cut into 4-μm sections. Tumor and bone areas were measured from mid-sagittal sections of each tibia stained with hematoxylin and eosin (H&E; Harris hematoxylin, CellPath) or Masson–Goldner Trichrome (MGT), using MetaMorph image analysis software (Molecular Devices, LLC).

Multinucleated (>1 nuclei) osteoclasts in the tumor-bone interface were counted in TRACP (tartrate-resistant acid phosphatase)-stained sections and normalized to the length of the tumor-bone interface. The whole section was analyzed. Osteoclasts were counted from MGT-stained sections based on morphology and location. Two microscope fields at ×10 magnification were analyzed.

The effect of radium-223 on inducing DNA double-strand breaks was evaluated by immunohistochemical staining of γ-H2AX molecules (JBU301, Millipore) as previously described (14). Four microscope fields (when possible) were counted for γ-H2AX-positive tumor cells using ×40 objective. γ-H2AX positive osteoblasts and multinucleated osteoclasts on bone were counted in TRACP and γ-H2AX double-stained sections. Samples (n = 6/group) were obtained from mice sacrificed at 24, 48, or 72 hours after radium-223 administration, and analyzed in one mid-sagittal section per sample using Leica DM4000 B Research Microscope (Leica Microsystems).

For autoradiography, undecalciﬁed tibiae (n = 6/group) from radium-223-treated mice sacriﬁced at 24, 48, or 72 hours post dosing were embedded in methyl methacrylate, cut into 4-μm-thick sections and after plastic removal dipped in Ilford K5 emulsion (Polysciences Inc.). The sections were then held in a light-protected box for 3 days at room temperature, processed according to manufacturer’s instructions and counterstained with MGT staining.

Radiographic and micro-CT imaging
Radiography was performed at two weeks and at sacriﬁce (days 22–25) and micro-CT imaging at sacriﬁce. For radiography, the animals were anesthetized by inhalation of isoflurane and x-rayed in an anteroposterior position using the Faxitron Specimen Radiographic System Mx-20 D12 (Faxitron Corp.) with Faxitron Dicom 3.0 software. At least one radiograph (both hind limbs) per animal were taken at each analysis point (34 kV, 7 seconds, 2-fold magnification). The formation of tumor-induced osteoblastic, mixed and osteolytic changes in bone (lesion area) was determined from the images with the MetaMorph software. Micro-CT measurements on the fixed tibiae were performed using SkyScan 1072 scanner (Bruker) using voxel size of 7 μm. The measurement region was 6-mm wide, starting from 0.2 mm below the growth plate and the lower threshold for total bone intensity was 80. Trabecular and cortical bone could not be analyzed separately due to the massive destruction of normal bone architecture in the control group. Thus, only total bone was analyzed with lower intensity threshold of 80.

Statistical methods
Statistical analysis was performed with statistical software R (ref. 15; version 3.1.0 or newer). All statistical analyses were performed as two-sided tests. For end-point analyses, data normality and homogeneity of variance were evaluated before further analyses. In the case of violating these assumptions, either log or other appropriate transformation (e.g., square root, reciprocal) was applied. If the assumptions were fulﬁlled as such or after a transformation, the group comparisons were carried out using one-way ANOVA followed by Tukey’s HSD post hoc test (in the case of statistically signiﬁcant ANOVA; P < 0.05). If the assumptions were not fulﬁlled, Kruskal–Wallis test followed by the Mann–Whitney U test for pairwise comparisons (in the case of signiﬁcant Kruskal–Wallis test; P < 0.05) were used. If an analysis contained only one comparison, either the Student t test (normally distributed data) or the Mann–Whitney U test (non-normal data) was applied. For the analysis of the proportion of animals with visceral metastases, Fisher’s exact test was used. The parameters assessed in multiple time points as well as total activities between control and tumor-bearing tibiae were analyzed using either fixed or mixed models (estimated using R package nlme (16). The hypotheses (e.g., comparisons between two groups at speciﬁc time points) were tested using model contrasts. In the case of multiple comparisons, the P values were adjusted to avoid false positives. Contrasts and the corresponding P values were computed using R package multcomp (17).

Results
Radium-223 inhibits tumor growth in prostate cancer mouse models
The effects of radium-223 on tumor growth were investigated in LNCaP cell line and LuCaP 58 PDX models in mice...
Figure 1.
Radium-223 suppresses LNCaP and LuCaP 58 prostate cancer growth in bone in mouse models. 

**A**, Serum PSA levels in mice bearing LNCaP tumors, measured biweekly during dosing (mean ± SD, n = 10–14, P = 0.02771).

**B**, Serum PSA levels in mice bearing LuCaP 58 PDX tumors, measured biweekly during dosing (mean ± SD, n = 16–18, P = 0.00191).

**C**, Tumor area in mice bearing LNCaP tumors (n = 12–13, P = 0.00928).

**D**, Tumor area in mice bearing LuCaP 58 tumors (n = 11, P = 0.09817).

**E**, Total tissue area in mice bearing LNCaP tumors (n = 7–10, P = 0.91945).

**F**, Total tissue area in mice bearing LuCaP 58 tumors (n = 11, P = 0.0697).

**G**, The length of tumor-bone interface in mice bearing LNCaP tumors (n = 6–10, P = 0.00122).

**H**, The length of tumor-bone interface in mice bearing LuCaP 58 tumors (n = 8–11, P = 0.00014). In box plots, horizontal lines show 5th, 25th, 50th, 75th, and 95th centiles and crosses indicate mean values; ns = not significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001.
Figure 2.
Radium-223 inhibits tumor-induced osteoblastic reaction resulting from LNCaP and LuCaP 58 prostate cancer growth in bone in mice. A and B, Representative micro-CT reconstructions of healthy and tumor-bearing tibiae in (A) LNCaP and (B) LuCaP 58 models imaged from the medial side (measurement area starting 0.5 mm below the growth plate). Respective sagittal sections are shown on the right. Bone volume of tibiae in mice bearing (C) LNCaP (n = 12–13, P = 0.00450) or (D) LuCaP 58 (n = 8–10, P < 0.001) tumors. In box plots, horizontal lines show 5th, 25th, 50th, 75th, and 95th centiles and crosses indicate mean values. Representative radiographs of healthy and tumor-bearing tibiae in (E) LNCaP and (F) LuCaP 58 models. Red line delineates the osteoblastic/osteolytic/mixed lesion area.

Lesion area measured biweekly during dosing in mice bearing (G) LNCaP tumors (mean ± SD, n = 11–17, P = 0.01702) and (H) LuCaP 58 tumors (mean ± SD, n = 11–17, P = 0.00548). I, PINP levels in mice bearing LNCaP tumors were measured biweekly (mean ± SD, n = 11–15, P < 0.001). J, PINP levels in mice bearing LuCaP 58 tumors were measured biweekly (mean ± SD, n = 11–15, P < 0.001).
(Supplementary Table S1). Serum PSA levels and lesion areas (osteoblastic, mixed, and osteolytic changes in bone determined using radiography) were measured biweekly and tumor growth was evaluated histologically. Mice treated with radium-223 (300 kBq/kg, twice with 4-week interval) exhibited lower serum PSA levels in comparison with vehicle control (LNCaP, \( P = 0.02771 \); LuCaP 58, \( P = 0.00191 \); Fig. 1A and B). Despite the clear reduction compared with control, PSA level remained stable or increased during time course in radium-223-treated LNCaP and LuCaP 58 xenografts, respectively, similar to clinical...
Radium-223 inhibits tumor-induced bone formation in both LNCaP and LuCaP 58 xenograft models

SREs associated with prostate cancer growth in bone are caused by pathologic and structurally weak bone resulting from abnormal activation of both osteoclasts and osteoblasts by prostate cancer. To better understand the role of radium-223 in preventing the SREs, the effects of radium-223 on bone were investigated in LNCaP and LuCaP 58 xenograft models. In both models, mice administered with radium-223 at 300 kBq/kg, twice with 4-week interval, exhibited significantly reduced bone volume (LNCaP, \( P = 0.00450 \), 17% reduction; LuCaP 58, \( P < 0.001 \), 28% reduction), bone surface area (LNCaP, \( P < 0.001 \), 22% reduction; LuCaP 58, \( P < 0.001 \), 45% reduction), and bone surface density (LNCaP, \( P < 0.001 \), 21% reduction; LuCaP 58, \( P < 0.001 \), 30% reduction) in tumor-bearing tibiae in comparison with vehicle control, as measured by micro-CT (Fig. 2A–D). The lesion area consisting of mainly osteoblastic, but also mixed and osteolytic tumor-induced pathologic changes as observed by radiography was decreased in both LNCaP and LuCaP 58 xenografts (Fig. 2E–H). In addition, radium-223 treatment resulted in lower levels of bone formation biomarker PINP in LNCaP (\( P < 0.001 \)) and LuCaP 58 (\( P = 0.00548 \)) models in comparison with untreated animals (Fig. 2I and J). These results indicate that radium-223 suppresses the normal bone formation in tumor microenvironment.

The beneficial effect of radium-223 on tumor-induced pathologic bone effects was further supported by histomorphometry of LNCaP and LuCaP 58 tumor-bearing tibiae showing markedly reduced total bone area (LNCaP, \( P < 0.00059 \), 16% reduction; LuCaP 58, \( P = 0.059 \), 30% reduction) and relative trabecular bone area (LNCaP, \( P = 0.00564 \), 12% reduction; LuCaP 58, \( P = 0.0212 \), 56% reduction) in LNCaP and LuCaP 58 models in comparison with vehicle control (Fig. 3A–E). Similarly to tumor area, the reduction in total bone area was not significant in LuCaP 58 model. Histological analyses revealed that tibiae were filled with LuCaP 58 tumor and additional ectopic tumor growth was observed (Fig. 3A and B), resulting in higher total tissue area in these mice compared with LNCaP xenografts (Fig. 1E and F). With regard to bone cells, radium-223 reduced the number of osteoblasts relative to bone surface in histologic sections of bone metastases in both models (Fig. 3F and G; LNCaP, \( P = 0.00127 \), 90% reduction; LuCaP 58, \( P = 0.0014 \), 77% reduction) and a total eradication of osteoclasts at tumor-bone interface was observed in LNCaP model (\( P = 0.01207 \)) in response to radium-223 therapy. In contrast, in LuCaP 58 xenografts no difference was observed (\( P = 0.19644 \)) in the number of osteoclasts relative to tumor-bone interface in response to radium-223 therapy (Fig. 3H and I), although the tumor-bone interface length and thus also the absolute number of osteoclasts at tumor-bone interface was decreased (\( P = 0.00106 \), 61% reduction). Taken together, these data demonstrate that radium-223 decreases the tumor-induced pathologic bone formation by suppressing the accelerated bone turnover in tumor-bearing tibiae.

Interestingly, unlike radium-223, abiraterone treatment was not able to reduce tumor growth or pathologic bone changes in intratibial LuCaP 58 PDX model (Supplementary Fig. S1, Supplementary Table S2), suggesting that radium-223 could be a potential option for patients with acquired abiraterone resistance.

Visceral metastases in radium-223–treated mice

To evaluate the effect of radium-223 in the development of metastases in soft tissue, mice bearing LuCaP 58 cells were macroscopically evaluated for visceral metastases. The number of mice affected by visceral spread was lower in the radium-223 treatment group; however, the differences were not statistically significant (Fig. 4). In mice bearing LNCaP cells, tumor growth was not observed in other sites than in the inoculated tibiae.

Radium-223 is deposited in the intratubular bone matrix, allowing local targeting of \( \alpha \) particles

The localization of radium-223 dichloride particles within osteoblastic tumors was studied by autoradiography in mice sacrificed at 24, 48, and 72 hours after single intravenous administration of radium-223. In mice intratibially inoculated with LuCaP 58 cells, a vast majority of radium-223 deposits was observed within the bone matrix and especially in the vicinity of activated osteoblasts. In addition, a few radium-223 deposits co-localized with prostate cancer cells (Fig. 5A). The mean value for total activity (gamma counts per minute) was higher in tumor-bearing tibiae compared with control non-tumored tibiae at 24 and 48 hours (Fig. 5B; 24 hours, \( P = 0.00590 \); 48 hours, \( P = 0.00332 \)).

A single radium-223 injection induces immediate effects on tumor cells, osteoblasts, and osteoclasts in prostate cancer growing in bone

The immediate effects on tumors were studied after a single dose of radium-223 in LuCaP 58 tumor-bearing mice. Interestingly, radium-223 decreased serum PSA level in comparison with vehicle control (\( P = 0.04926 \)) at 72 hours post injection (Fig. 5C). Furthermore, there was a trend for increased relative necrotic tumor area in tumor-bearing tibiae over time, although significance was not reached (Fig. 5D). The effect of radium-223 on inducing DNA double-strand breaks was evaluated by immunohistochemical staining of \( \gamma \)-H2AX molecules in LuCaP 58 tumor-bearing tibiae (14). DNA double-strand breaks were increased in tumor cells at all time points (\( P = 0.00297 \), 0.03665, and 0.00714
for 24, 48, and 72 hours, respectively) and in osteoblasts and osteoclasts at 72 hours after dosing ($P = 0.03148$ and 0.00071, respectively), compared with vehicle-treated mice at 72 hours (Fig. 5E–G).

**Discussion**

Metastasis to bone has detrimental effects on bone, quality of life, and survival (20, 21). Although currently used palliative therapies for bone metastases in CRPC, such as zoledronic acid and the RANK-L inhibitor denosumab, are capable of reducing SREs and provide pain palliation (22–25), the targeted alpha therapy radium-223 is the first drug with proven beneficial effect on overall survival (10). However, it has not been yet investigated in detail whether the beneficial clinical effects in prostate cancer patients are solely due to radium-223 affecting osteoblasts and/or osteoclasts, or if the treatment also has a direct effect on prostate cancer cells. Our results from preclinical studies with two different prostate cancer xenograft models, LNCaP representing osteoblastic/mixed lesions and LuCaP 58 PDX representing osteoblastic lesions, demonstrate marked tumor growth suppression, and inhibition of tumor-induced bone alteration in radium-223-treated animals. We have previously reported similar findings with radium-223 treatment in a mouse model of osteolytic breast cancer bone metastasis (12), indicating that radium-223 is effective regardless of the primary tumor origin and the type of tumor-induced pathological effects on bone. In addition to the distinct tumor-induced reactions in bone, the observed differences in certain parameters may derive from the use of different mouse strains and distinct properties of the tumor cells. LNCaP is a cell line-derived model whereas LuCaP 58 model represents a PDX model. Furthermore, LuCaP 58 tumors grow very aggressively in comparison with LNCaP tumors, resulting in extra-osseous tumor growth and consecutively increased total tissue area.

Radium-223 uptake was recently characterized in healthy mice as well as in osteoblastic (LNCaP) and osteolytic (PC3) prostate cancer–bearing animals (26). This study showed that bone, specifically the areas of active bone remodeling and vascular supply, is the main target site for radium-223 accumulation. In mice with prostate cancer growing in bone, radium-223 accumulated on the bone surface next to the malignant site (26). Here, we assessed radium-223 deposition pattern in LuCaP 58 model representing a very strong osteoblastic component and demonstrated the efficient deposition of radium-223 into the intratrabecular bone matrix, with the most substantial occurrence in the proximity of activated osteoblasts. A portion of radium-223 deposits was found in the midst of prostate cancer cells. The deposition pattern was in agreement with the increased uptake measured using gamma counter. However, the extent and nature of co-localization with tumor cells remains to be elucidated. The localization of radium-223 to the bone microenvironment adjacent to tumor, combined with the short track length of α-ray (2–10 cell diameters, < 100 µm), effectively limits the damage only to adjacent cells. This is further substantiated by high tolerability in mice and a low rate of hematological side effects in clinical trials with radium-223 (27–30).

Radium-223 induced DNA double-strand breaks in tumor cells 24, 48, and 72 hours after dosing in mice bearing LuCaP 58 tumors. In addition, serum PSA level compared with vehicle control was decreased already at 72 hours post treatment, indicating that the induction of DNA double-strand breaks is associated with significant tumor cell death. Furthermore, clear tumor necrosis was observed in tumor-bearing tibiae treated with radium-223. The observed radium-223 deposition pattern, together with its early effects on tumor cells, osteoblasts and osteoclasts, suggests direct and potent radiation effects on both tumor and bone cells in osseous tumor growth.

In addition to bone metastases, prostate cancer also causes visceral metastases to soft tissue in approximately 20% of patients participating in first-line studies for CRPC (31–33). Additional preclinical studies are necessary to investigate the possible roles and mode-of-action of radium-223 in inhibiting overall metastatic spread. The ability of radium-223 to trigger tumor cell death and to prevent both osteolytic and osteoblastic metastasis progression in the bone as well as secondary metastases to soft tissues concurrently would render this agent a very powerful therapy in the treatment of diverse solid tumors.

The observed decreases in both overall tumor burden as measured by PSA and in pathologic bone changes as determined using the bone formation marker PINP in response to radium-223 treatment are in line with changes in PSA and alkaline phosphatase (ALP) observed in clinical setting (18, 19). Our preclinical data also suggest a dependency between decreased osteoblastic activity and decreased tumor burden in radium-223–treated mice as measured by various parameters reflecting pathologic bone formation and tumor growth, respectively. Future studies with larger treatment groups are needed to determine if there is an association between ALP and response to radium-223.

There are currently multiple therapies with very distinct mechanisms of actions and unique toxicities available for the treatment of CRPC (5, 10, 31–38). Regrettably, clinical
Radium-223 Mode-of-Action in Prostate Cancer

A

B

C

D

E

F

G

www.aacrjournals.org Clin Cancer Res; 2017

OF9

Published OnlineFirst March 31, 2017; DOI: 10.1158/1078-0432.CCR-16-2955

Radium-223 Mode-of-Action in Prostate Cancer

www.aacrjournals.org

Downloaded from cincancerres.aacrjournals.org on October 15, 2017. © 2017 American Association for Cancer Research.
Radium-223 is active in abiraterone-resistant prostate cancer, excluding the unlikely possibility that abiraterone resistance impairs the efficacy of radium-223. Resistance has not been described in clinical situations, such as ATM and BRCA2 (39).

Figure 6.
Radium-223 therapy exhibits a dual targeting mode-of-action that destroys tumor cells and inhibits tumor-induced pathologic bone reaction. A, Tumor-induced dysregulation of bone remodeling is a key driver in prostate cancer-derived bone metastases. Prostate cancer bone metastases are commonly associated with abnormal osteoblastic bone growth. Prostate cancer cells release paracrine factors that affect both osteoblastic and osteoclastic activity and stimulate abnormal bone remodeling. Osteoblasts, in turn, secrete factors that promote progression of the prostate cancer metastases and stimulate osteoclast activity. The growth factors released from bone by activated osteoclasts further stimulate tumor growth. This complex vicious cycle of prostate cancer bone metastasis results in increased tumor growth and altered bone structure stability, resulting eventually in bone destruction. RANKL, receptor activator of nuclear factor kappa-B ligand. B, Radium-223 is a targeted alpha therapy with a dual targeting mode-of-action. Radium-223 inhibits the vicious cycle of prostate cancer bone metastases by inducing tightly localized cytotoxic effects through double-stranded DNA breaks in osteoblasts, osteoclasts, and prostate cancer cells.

**Table 5.**

<table>
<thead>
<tr>
<th>Group</th>
<th>Prostate Cancer Cells</th>
<th>Osteoblasts</th>
<th>Osteoclasts</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>100</td>
<td>90</td>
<td>80</td>
</tr>
<tr>
<td>Radium-223</td>
<td>50</td>
<td>80</td>
<td>60</td>
</tr>
</tbody>
</table>

Application has revealed that a large number of patients acquire resistance to most therapies after a short period of treatment and moreover, multiple patients exhibit de novo resistance. Of note, our data, similarly to clinical situation show that radium-223 is active in abiraterone-resistant prostate cancer, excluding the unlikely possibility that abiraterone resistance impairs the efficacy of radium-223. Resistance has not been described in association with alpha therapy. However, the impact of genetic alterations, such as mutations in or copy-number variation of DNA repair mechanism genes, on the antitumor efficacy of radium-223 treatment in preclinical and clinical studies needs to be elucidated. For example, publicly available genomic data in LNCaP cells reveal several defects in DNA repair genes, such as ATM and BRCA2 (39).
Radium-223 was recently shown to induce T-cell–mediated lysis in human prostate, breast, and lung carcinoma cells (40). In our study with preclinical CRPC models established in immunocompromised mice, the host immune response and potential immunotherapeutic role of radium-223 in prostate cancer could not be addressed. Additional preclinical studies using immunocompetent mice will be useful in evaluating the immunotherapeutic effects of radium-223 in prostate cancer and the efficacy of radium-223 in combination with immune checkpoint inhibitors, such as PD-(L)1 inhibitors. Clinical evaluation of this is currently ongoing in a Phase I study evaluating the safety and tolerability of radium-223 in combination with atezolizumab (NCT028814669).

Taken together, our results indicate that radium-223 therapy exhibits a dual targeting mode-of-action that inhibits disease progression via tightly localized cytotoxic effects on tumor cells and stabilization of the bone microenvironment in bone metastases (Fig. 6).

On the basis of clinical findings, our previously published results (12) and the data presented here, the potential of radium-223 in delaying time to SREs and bone metastases in patients with earlier phase of prostate cancer and also in patients with bone metastases from other solid tumors need to be evaluated. The focus of investigation is now on developing optimal combinations of the new therapeutic agents to effectively target the primary tumor as well as prevent metastasis to bone, resulting in increased survival and lower patient morbidity. Preliminary data from a post-hoc study exhibited improved overall survival in patients treated with radium-223 and concomitant abiraterone, enzalutamide, or denosumab, raising positive expectations for further research (30).

Disclosure of Potential Conflicts of Interest

M.I. Suominen, K.M. Fagerlund, J.P. Rissanen, and J.M. Halleen hold ownership interest (including patents) in Pharmasset Services Ltd. D. Mumberg and A. Scholz hold ownership interest (including patents) in Bayer AG. No potential conflicts of interest were disclosed by the other authors.

Authors’ Contributions

Conception and design: M.I. Suominen, J.P. Rissanen, D. Mumberg, K. Ziegelbauer, S.-M. Kåkönen, A. Scholz

Development of methodology: M.I. Suominen, K.M. Fagerlund, E. Corey, A. Scholz

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): M.I. Suominen, Y.M. Konkol, J.P. Morko, Z. Peng

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): M.I. Suominen, E.J. Alhoniemi, S.K. Laine, S.-M. Kåkönen, A. Scholz


Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): K.M. Fagerlund, J.P. Rissanen, Y.M. Konkol, S.K. Laine, E. Corey, S.-M. Kåkönen

Study supervision: S.-M. Kåkönen, J.M. Halleen, A. Scholz

Acknowledgments

The authors thank Natalia Habilainen-Kirillov, Riikka Kytömaa, Anniina Luostarinen, Johanna Osling, and Jani Seppänen for their skillful technical assistance. Aurexel Life Sciences Ltd. (www.aurexel.com) is acknowledged for the editorial support funded by Bayer AG.

Grant Support

The establishment of the LuCap 58 PDX was supported by grants from the National Institutes of Health (to E. Corey, National Institutes of Health, NIHPO1 CA085859 and NIHPO1 CA163227). Bayer AG has paid Pharmasset Services Ltd. for the execution of the experiments. Editorial support was funded by Bayer AG.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received November 28, 2016; revised January 5, 2017; accepted March 29, 2017; published OnlineFirst March 31, 2017.


Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models


Clin Cancer Res  Published OnlineFirst March 31, 2017.

Updated version  
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-16-2955

Supplementary Material  
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2017/03/31/1078-0432.CCR-16-2955.DC1

E-mail alerts  
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.